MAJI: Ushering In A New Era With Transformative Biotech Acquisition
A significant transformation is underway for the OTC PINK listed $MAJI. The company is executing a high-profile acquisition of Exousia Pro, Inc. (EXO), a biotech venture at the forefront of next-generation medicine. With a new direction rooted in cutting-edge biotech, an imminent name change, and this transformative acquisition, MAJI is positioning itself to deliver what could be a breakthrough in modern healthcare.
At the heart of this transformation is EXO’s exclusive worldwide rights to patent-pending technology that utilizes exosomes – tiny, natural nanoparticles capable of delivering genetic material directly to diseased cells and tissues. This innovative platform, which harnesses both mammalian and plant-based exosomes, has the potential to address some of today’s most challenging health conditions, including cancer and cardiovascular diseases.
Why is this technology generating so much attention from researchers and clinicians? Exosomes act as the body’s natural delivery system, transporting genetic instructions and molecular cargo between cells. EXO’s proprietary advancements take this one step further by engineering exosomes to “carry” therapeutic molecules – such as DNA or mRNA – and deliver them precisely to their targets. By reducing off-target effects and improving delivery efficiency, this technology promises a level of precision that traditional treatments often lack.
This potential is grounded in the collaboration that brought it to life. EXO is a joint venture of Progenicyte Japan, a biotechnology firm renowned for its work in genetic engineering, regenerative medicine, and advanced drug delivery systems. Progenicyte Japan’s collaborations with the University of Florida and Kyoto University bring world-class academic expertise and intellectual resources to EXO’s mission. Together, they are pushing the boundaries of what exosome technology can achieve – not just in oncology, but also in areas such as Alzheimer’s disease and Down syndrome.
Marijuana Inc
The acquisition is further bolstered by the company’s efforts to set the stage for success in its new era. Plans to pursue SEC reporting status and adopt a leaner share structure – from 750 million authorized shares down to 250 million – demonstrate a commitment to transparency and a more shareholder-friendly framework. Updates on the OTC Markets platform are already in progress, and the company has announced plans for a name change and a new website launch set for January 1, 2025.
This transformation is unfolding at a time when the healthcare industry is eager for breakthrough solutions. Many existing treatments struggle to deliver therapeutic agents precisely where they are needed, leading to limited efficacy and unwanted side effects. EXO’s exosome-based approach offers a highly tailored solution, potentially overcoming these challenges. For example, the company has indicated interest in glioblastoma, a particularly aggressive form of brain cancer, where targeted therapies could offer new hope for patients.
With its new brand set to launch on January 1, 2025, MAJI is ready to step into the biotech space with purpose. The acquisition of EXO brings advanced exosome technology to the forefront, positioning the company to address some of medicine’s toughest challenges, including cancer, Alzheimer’s, and glioblastoma. This launch represents a key moment in MAJI’s transformation and potentially a major step forward for modern healthcare.
*This article has been cross-published from DegenMag.com; See all disclosures and disclaimers here
https://x.com/DegenMagazine/status/1868558821729149089
News 
Market Data 
Discover 
AI
